Literature DB >> 26385785

Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma: comparison with (99m)Tc-MIBI scintigraphy.

Hiroshi Wakabayashi1, Junko Saito2, Junichi Taki3, Nanako Hashimoto2, Hiroyuki Tsuchiya4, Toshifumi Gabata2, Seigo Kinuya3.   

Abstract

OBJECTIVE: This study aims to determine whether (99m)Tc-MIBI scintigraphy and triple-phase contrast-enhanced magnetic resonance imaging (TCE-MRI) performed during and after preoperative chemotherapy have the power to predict final chemotherapeutic effects in patients with osteosarcoma (OS).
MATERIALS AND METHODS: Seventeen patients underwent (99m)Tc-MIBI scintigraphy and TCE-MRI before and after the middle and last courses of preoperative chemotherapy. As for (99m)Tc-MIBI scintigraphy, an uptake ratio (UR) and a reduction rate of URUR(MIBI)) were calculated. As for TCE-MRI, a ratio of contrast to background (CTB) was calculated in the whole tumor area (WA) at each phase on dynamic T1-weighted fat suppression images. Then a ratio of signal (R(WA)) was calculated by dividing CTB at triple-phase by CTB at pre-phase.
RESULTS: Nine and eight patients showed good and poor response in histopathologic evaluation. The sensitivity, specificity, and accuracy for the prediction of histopathological chemotherapeutic effect was 44, 100, 69% in R(WA) at the first phase, 100, 75, 88% in ΔUR(MIBI) after the middle course, 88, 100, 94% in R(WA) at the first phase, and 100, 75, 88% in ΔUR(MIBI) after the last course of the preoperative chemotherapy, respectively.
CONCLUSION: Both (99m)Tc-MIBI scintigrapy and TCE-MRI can predict the tumor response in patients with OS after the completion of the preoperative chemotherapy.

Entities:  

Keywords:  99mTc-MIBI; Osteosarcoma; Preoperative chemotherapy; Triple-phase contrast-enhanced MRI

Mesh:

Substances:

Year:  2015        PMID: 26385785     DOI: 10.1007/s00256-015-2250-1

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  28 in total

1.  Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy.

Authors:  P Ongolo-Zogo; P Thiesse; J Sau; C Desuzinges; J Y Blay; A Bonmartin; M Bochu; T Philip
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

2.  Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.

Authors:  Hyung Jun Im; Tae Sung Kim; Seog-Yun Park; Hye Sook Min; June Hyuk Kim; Hyun Guy Kang; Seung Eun Park; Mi Mi Kwon; Jong Hyung Yoon; Hyeon Jin Park; Seok-ki Kim; Byung-Kiu Park
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-28       Impact factor: 9.236

Review 3.  Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation.

Authors:  B D Fletcher
Journal:  AJR Am J Roentgenol       Date:  1991-10       Impact factor: 3.959

Review 4.  Imaging assessment of osteosarcoma in childhood and adolescence: diagnosis, staging, and evaluating response to chemotherapy.

Authors:  Farzin Eftekhari
Journal:  Cancer Treat Res       Date:  2009

Review 5.  Osteosarcoma: the COSS experience.

Authors:  Stefan Bielack; Herbert Jürgens; Gernot Jundt; Matthias Kevric; Thomas Kühne; Peter Reichardt; Andreas Zoubek; Mathias Werner; Winfried Winkelmann; Rainer Kotz
Journal:  Cancer Treat Res       Date:  2009

6.  Prognostic value of Tc-99m-MIBI performed during middle course of preoperative chemotherapy in patients with malignant bone and soft-tissue tumors.

Authors:  Hiroshi Wakabayashi; Junichi Taki; Anri Inaki; Hisashi Sumiya; Yoh Zen; Hiroyuki Tsuchiya; Seigo Kinuya
Journal:  Clin Nucl Med       Date:  2012-01       Impact factor: 7.794

Review 7.  Bone and soft tissue tumors: the role of contrast agents for MR imaging.

Authors:  K L Verstraete; P Lang
Journal:  Eur J Radiol       Date:  2000-06       Impact factor: 3.528

Review 8.  Bone tumors in adolescents and young adults.

Authors:  Stefan S Bielack; Dorothe Carrle; Jendrik Hardes; Andreas Schuck; Michael Paulussen
Journal:  Curr Treat Options Oncol       Date:  2008-05-01

Review 9.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

10.  The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma.

Authors:  Carmelo Caldarella; Marco Salsano; Maria Antonietta Isgrò; Giorgio Treglia
Journal:  Int J Mol Imaging       Date:  2012-09-13
View more
  5 in total

1.  99mTc-MIBI Scintigraphy for the Preoperative Assessment of Histological Response to Neoadjuvant Chemotherapy in Patients With Osteosarcoma: A Systematic Review and a Bivariate Meta-Analysis.

Authors:  Fashuai Wu; Yu Huang; Xin Huang; Silang Fang; Xiaohui Huang; Xin Huang; Zhicai Zhang; Zengwu Shao
Journal:  Front Oncol       Date:  2020-05-22       Impact factor: 6.244

2.  Usefulness of Quantitative Bone Single Photon Emission Computed Tomography/Computed Tomography for Evaluating Response to Neoadjuvant Chemotherapy in a Patient with Periosteal Osteosarcoma.

Authors:  Kazuhiro Kitajima; Hiroyuki Futani; Masayuki Fujiwara; Go Minakawa; Yuko Osugi; Tatsuya Tsuchitani; Koichiro Yamakado
Journal:  Cureus       Date:  2018-11-28

3.  Monitoring Response to Neoadjuvant Chemotherapy of Primary Osteosarcoma Using Diffusion Kurtosis Magnetic Resonance Imaging: Initial Findings.

Authors:  Chenglei Liu; Yan Xi; Mei Li; Qiong Jiao; Huizhen Zhang; Qingcheng Yang; Weiwu Yao
Journal:  Korean J Radiol       Date:  2019-05       Impact factor: 3.500

Review 4.  How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.

Authors:  Heike E Daldrup-Link; Ashok J Theruvath; Ali Rashidi; Michael Iv; Robbie G Majzner; Sheri L Spunt; Stuart Goodman; Michael Moseley
Journal:  Pediatr Radiol       Date:  2021-05-27

5.  Prediction and evaluation of neoadjuvant chemotherapy using the dual mechanisms of 99mTc-MIBI scintigraphy in patients with osteosarcoma.

Authors:  Caixia Wu; Qian Wang; Yuan Li
Journal:  J Bone Oncol       Date:  2019-07-09       Impact factor: 4.072

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.